



JPW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 17703	
In Re Application Of: Maria Cristina Geroni, et al.					
					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/500,606 ✓	June 30, 2004	Unassigned	23389	1614	4724
Title: COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17703

In Re Application of: **Maria Cristina Geroni, et al.**



Application No. 10/500,606	Filing Date June 30, 2004	Examiner Unassigned	Customer No. 23389	Group Art Unit 1614	Confirmation No. 4724
--------------------------------------	-------------------------------------	-------------------------------	------------------------------	-------------------------------	---------------------------------

Title:

COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa	
(Date)	
Signature	
Typed or Printed Name of Person Signing Certificate	

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on	
March 15, 2006	
(Date)	
Signature of Person Mailing Correspondence	
Peter I. Bernstein	
Typed or Printed Name of Person Mailing Certificate	

***This certificate may only be used if paying by deposit account.**


Signature

Dated: **March 15, 2006**

Peter I. Bernstein
Registration No. 43,497
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

cc:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Maria Cristina Geroni, et al. **Examiner:** Unassigned
Serial No.: 10/500,606 **Art Unit:** 1614
Filed: June 30, 2004 **Docket:** 17703
For: COMBINED THERAPY AGAINST **Dated:** March 15, 2006
TUMORS COMPRISING SUBSTITUTED
ACRYLOYL DISTAMYCIN
DERIVATIVES AND PROTEIN
KINASE (SERINE/THREONINE KINASE) INHIBITORS

Confirmation No.: 4724

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. PCT International Publication No. WO 01/97789 A2, published December 27, 2001;
2. PCT International Publication No. WO 01/97790 A2, published December 27, 2001;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 15, 2006

Peter I. Bernstein

3. Ciomei M. et al., "Decreased Tyrosine Phosphorylation in Tumour Cells Resistant to FCE 24517 (Tallimustine)", *British Journal of Cancer*, 72:1504-1508 (1995);
4. Marchini S. et al., " α -Bromoacryloyl Derivative of Distamycin a (PNU 151807): A New Non-Covalent Minor Groove DNA Binder With Antineoplastic Activity", *British Journal of Cancer*, 80(7):991-997 (1999);
5. García A.R. et al., "Structure and Synthesis of Distamycin A", *Nature*, 203:1064-1065 (1964);
6. Arcamone F.M. et al., "Synthesis, DNA-Binding Properties, and Antitumor Activity of Novel Distamycin Derivatives", *J. Med. Chem.*, 32:774-778 (1989);
7. PCT International Publication No. WO 90/11277, published October 4, 1990;
8. PCT International Publication No. WO 98/04524, published February 5, 1998;
9. PCT International Publication No. WO 98/21202, published May 22, 1998;
10. PCT International Publication No. WO 99/50265, published October 7, 1999;
11. PCT International Publication No. WO 99/50266, published October 7, 1999;
12. PCT International Publication No. WO 01/40181 A1, published June 7, 2001;
13. Druker B.J. et al., "Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia", *The Journal of Clinical Investigation*, 105(1):3-7 (2000); and
14. Arbuck S.G. et al., "New Targets for Cancer Chemotherapy", *Cancer Chemotherapy and Biological Response Modifier Annual 19 Chapter II*, 236-288 (2001).

Reference nos. 1-4 was cited in a Search Report dated April 1, 2003 received from the European Patent Office. Applicants are submitting a copy of the above-cited references. The Search Report was filed on June 30, 2004. The relevance of above-identified reference nos. 1-4 has been described in the Search Report. The relevance of above-identified reference nos. 5-14 has been described in the specification.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Peter I. Bernstein", with a long horizontal flourish extending to the right.

Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 7-80) PATENT AND TRADEMARK OFFICE

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. (Optional)

17703

Application Number

10/500,606

Applicant(s)

Maria Cristina Geroni, et al.

Filing Date

June 30, 2004

Group Art Unit

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 01/97789 A2	12/27/01	PCT			✓	
		WO 01/97790 A2	12/27/01	PCT			✓	
		WO 90/11277	10/4/90	PCT			✓	
		WO 98/04524	2/5/98	PCT			✓	
		WO 98/21202	5/22/98	PCT			✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


		Ciomei M. et al., "Decreased Tyrosine Phosphorylation in Tumour Cells Resistant to FCE 24517 (Tallimustine)", <i>British Journal of Cancer</i> , 72:1504-1508 (1995)
		Marchini S. et al., "α-Bromoacryloyl Derivative of Distamycin a (PNU 151807): A New Non-Covalent Minor Groove DNA Binder With Antineoplastic Activity", <i>British Journal of Cancer</i> , 80(7):991-997 (1999)
		García A.R. et al., "Structure and Synthesis of Distamycin A", <i>Nature</i> , 203:1064-1065 (1964)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**LIST OF PRIOR ART
CITED BY APPLICANT***(Use several sheets if necessary)***Atty. Docket No. (Optional)**

17703

Application Number

10/500,606

Applicant(s)

Maria Cristina Geroni, et al.

Filing Date

June 30, 2004

Group Art Unit

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
AA						
AB						

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/50265	10/7/99	PCT			✓	
	WO 99/50266	10/7/99	PCT			✓	
	WO 01/40181 A1	6/7/01	PCT			✓	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Arcamone F.M. et al., "Synthesis, DNA-Binding Properties, and Antitumor Activity of Novel Distamycin Derivatives", <i>J. Med. Chem.</i> , 32:774-778 (1989)
	Druker B.J. et al., "Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia", <i>The Journal of Clinical Investigation</i> , 105(1):3-7 (2000)
	Arbuck S.G. et al., "New Targets for Cancer Chemotherapy", <i>Cancer Chemotherapy and Biological Response Modifier Annual 19 Chapter II</i> , 236-288 (2001)

EXAMINER**DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.